Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520975 · ClinicalTrials.gov registry record · Phase 3
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT00520975: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00520975 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00520975, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
This randomized phase III trial studies first-line chemotherapy and trastuzumab to compare how well they work when given with or without bevacizumab in treating patients with breast cancer that overexpresses human epidermal growth factor receptor 2 (HER-2/NEU) and has spread to other areas of the body. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether giving first-line chemotherapy together with trastuzumab is more effective with or without bevacizumab in treating patients with metastatic breast cancer that overexpresses HER-2/NEU.
Interventions
- DRUG Carboplatin
- OTHER Placebo
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- BIOLOGICAL Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2007-11 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520975
The ClinicalTrials.gov registry entry for NCT00520975 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00520975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520975 about?
NCT00520975 is a clinical study titled "Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU". This randomized phase III trial studies first-line chemotherapy and trastuzumab to compare how well they work when given with or without bevacizumab in treating patients with breast cancer that overexpresses human epidermal growth factor receptor 2 (HER-2/NEU) and has spread to other areas of the bo...
What is the current status of trial NCT00520975?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2007-11. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00520975?
The interventions under investigation include: Carboplatin (DRUG), Placebo (OTHER), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00520975?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.